The mortality risk associated with higher hemoglobin: is the therapy to blame?
- PMID: 18756292
- DOI: 10.1038/ki.2008.263
The mortality risk associated with higher hemoglobin: is the therapy to blame?
Abstract
Recent trials have demonstrated a trend for increased mortality when patients with end-stage renal disease (ESRD) or chronic kidney disease (CKD) are treated with erythropoietin-stimulating agents (ESAs) to hemoglobin levels higher than recommended (>13 g/dl). Recent studies suggest that higher doses of ESAs, in themselves, may be at least partly responsible for this mortality risk. This is important, as more than 90% of patients with ESRD and approximately 20% of patients with CKD receive ESAs. Two new studies address this.
Comment on
-
Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease.Kidney Int. 2008 Sep;74(6):782-90. doi: 10.1038/ki.2008.245. Epub 2008 Jun 11. Kidney Int. 2008. PMID: 18547996 Free PMC article. Clinical Trial.
-
Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes.Kidney Int. 2008 Sep;74(6):791-8. doi: 10.1038/ki.2008.295. Epub 2008 Jul 2. Kidney Int. 2008. PMID: 18596733 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials